Cend Therapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
5
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$10M
Cend Therapeutics General Information
Description
Developer of a tumor-targeted tissue penetration drug intended to treat solid tumor cancers. The company offers technologies to enable more effective tumor-targeted, tissue-penetrating delivery of nucleic acid-based drugs, including targeted nanoparticle technologies to help protect and target delivery, providing clinicians with more effective treatment of difficult-to-treat solid tumor cancers.
Contact Information
Website
www.cendrx.comCorporate Office
- 12544 High Bluff Drive
- Suite 400
- San Diego, CA 92130
- United States
Corporate Office
- 12544 High Bluff Drive
- Suite 400
- San Diego, CA 92130
- United States
Cend Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 15-Sep-2022 | $10M | Completed | Clinical Trials - Phase 2 | ||
| 4. Later Stage VC (Series C) | 17-Sep-2020 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series B) | 27-Mar-2019 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 25-May-2018 | $1M | $2M | Completed | Clinical Trials - Phase 2 | |
| 1. Capitalization | 01-Jan-2015 | $1M | $1M | Completed | Startup |
Cend Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 371,396 | $0.000010 | $2.96 | $2.96 | 1x | $2.96 | 8.74% |
Cend Therapeutics Comparisons
Industry
Financing
Details
Cend Therapeutics Competitors (47)
One of Cend Therapeutics’s 47 competitors is Antag Therapeutics, a Venture Capital-Backed company based in Copenhagen, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Antag Therapeutics | Venture Capital-Backed | Copenhagen, Denmark | ||||
| PepGen | Formerly VC-backed | Boston, MA | ||||
| Apeptico | Formerly VC-backed | Vienna, Austria | ||||
| Oncorus | Formerly VC-backed | Andover, MA | ||||
| MBX Biosciences | Formerly VC-backed | Carmel, IN |
Cend Therapeutics Patents
Cend Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200282013-A1 | Low-dose cytokine co-administered with irgd for treating cancer | Inactive | 08-Mar-2019 | ||
| WO-2020185624-A1 | Low-dose cytokine co-administered with irgd for treating cancer | Inactive | 08-Mar-2019 |
Cend Therapeutics Signals
Cend Therapeutics Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Kyoto University Innovation Capital | Venture Capital | Minority |
Cend Therapeutics Acquisitions (1)
Cend Therapeutics’s most recent deal was a Merger/Acquisition with Impilo Therapeutics. The deal was made on 21-Sep-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Impilo Therapeutics | 21-Sep-2020 | Merger/Acquisition | Drug Discovery |
Cend Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Impilo Therapeutics | San Diego, CA | 2019 |
Cend Therapeutics FAQs
-
When was Cend Therapeutics founded?
Cend Therapeutics was founded in 2015.
-
Where is Cend Therapeutics headquartered?
Cend Therapeutics is headquartered in San Diego, CA.
-
What is the size of Cend Therapeutics?
Cend Therapeutics has 5 total employees.
-
What industry is Cend Therapeutics in?
Cend Therapeutics’s primary industry is Drug Discovery.
-
Is Cend Therapeutics a private or public company?
Cend Therapeutics is a Private company.
-
What is the current valuation of Cend Therapeutics?
The current valuation of Cend Therapeutics is .
-
What is Cend Therapeutics’s current revenue?
The current revenue for Cend Therapeutics is .
-
How much funding has Cend Therapeutics raised over time?
Cend Therapeutics has raised $11.1M.
-
Who are Cend Therapeutics’s investors?
Kyoto University Innovation Capital has invested in Cend Therapeutics.
-
Who are Cend Therapeutics’s competitors?
Antag Therapeutics, PepGen, Apeptico, Oncorus, and MBX Biosciences are some of the 47 competitors of Cend Therapeutics.
-
When was Cend Therapeutics acquired?
Cend Therapeutics was acquired on 15-Sep-2022.
-
Who acquired Cend Therapeutics?
Cend Therapeutics was acquired by Lisata Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process